Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

The incidence of leukemic conversion from PNH is estimated to be less than 3%. A patient had an extremely rare case of leukemic conversion from paroxysmal nocturnal hemoglobinuria (PNH). A report of ...

Patients with CLL and a CSHA CFS score greater than 3 had significantly higher rates of treatment interruption due to adverse effects. The CSHA Clinical Frailty Scale (CFS) is a valuable tool for ...